Systemically administrable GPX4 inhibitor KY0418 drives ferroptosis and suppresses tumors in vivo
Start here
Researchers have developed KY0418, a bioavailable inhibitor of GPX4 that can be administered systemically, published in Cell on 21 October 2026. GPX4 is a central regulator of ferroptosis, a form of iron-dependent cell death, and most inhibitors of it have been usable only in vitro. KY0418 induces ferroptosis across multiple in vivo models and suppresses tumor growth in a context-dependent manner. The work also connects systemic ferroptosis induction to tissue-level metabolic remodeling and presents evidence that metastatic spread can be inhibited. Which tumor contexts respond best to KY0418, how metabolic remodeling shapes its tolerability, and its translation toward clinical testing remain open questions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- CellPickA bioavailable GPX4 inhibitor for ferroptosis induction in vivo and tumor suppression
Researchers developed KY0418, a systemically deliverable GPX4 inhibitor that induces ferroptosis across multiple models and suppresses tumors in a context-dependent manner. The study links systemic ferroptosis induction to tissue metabolic remodeling and indicates that metastatic spread can also be inhibited.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 21 08:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.